.jpg)
.png)
I knew that Saturday when my pager went off with a “high priority” message, COVID-19 was here. In less than 24 hours, our regional chair restructured all that we do; four days hospital rounds, four days telemedicine, no outreach, work at one campus, days off requiring checking messages for updates of protocols, daily dashboard and system-wide town hall meetings. We were placed into teams to minimize exposure ultimately “to avoid all of us getting the virus at once.”
Article By:
Advanced Practitioner
Geisinger Cardiology
Geisinger Heart and Vascular Center
Geisinger Wyoming Valley Medical Center
Wilkes Barre, PA
Multiple randomized controlled trials have demonstrated significant reductions in major cardiovascular (CV) events and mortality with statin therapy.(1) These data have supported the “LDL-C treatment strategy,” in which CV event risk reduction is directly proportionate to the extent of LDL-C lowering.(2) Because the majority of these trials studied fixed-dose statin regimens, this approach became the foundation of initial treatment recommendations within the 2013 ACC/AHA Guideline on the Trea
Article By:
PGY2 Ambulatory Care Pharmacy Resident
University of Colorado
Anschutz Medical Campus
Aurora, CO
President, National Lipid Association
Professor and Vice Chair
Department of Clinical Pharmacy
Professor, Department of Family Medicine
University of Colorado
Anschutz Medical Campus
Aurora, CO
Cholesterol is an essential component of human cell biology, responsible for numerous diverse and important physiologic functions. In addition to maintenance of cell membranes, cholesterol is a key substrate for production of vitamin D, and thyroid and steroid hormones. Previous studies hypothesized adrenal insufficiency may occur in individuals with LDL/HDL deficiency, although little data is available.
Article By:
Clinical Scientist
Cook Children’s Medical Center
Fort Worth, TX
Medical Student
University of North Texas
Health Science Center
Fort Worth, TX
Endowed Chair
Cardiovascular Health and Risk
Prevention Program
Cook Children’s Medical Center
Fort Worth, TX
Diplomate, American Board of Clinical Lipidology
Here we describe a case study of a 50- year-old physically active male wit h no significant past medical history wh o presented initially with fatigue an d shortness of breath while playing tenni s and was found to have new findings of an inferior wall MI on EKG. He wa s referred to Cardiology for a nuclea r stress study which showed a moderat e sized, severe fixed inferior wall defect. He had well-preserved functional exercis e capacity during the study.
Article By:
Internal Medicine Resident Physician
Christiana Care
Newark, DE
Cardiology
Christiana Care Health System
Newark, DE
Diplomate, American Board of Clinical Lipidology
We present a clinical case and offer Practical Pearls from primary care/Lipid Specialist and cardiology for management of a common scenario, reinforcing the importance of a clinician-patient discussion.
Key points:
Article By:
Past President, Southeast Lipid Association
Medical Director, Hometown Direct Care
Hometown Direct Consulting
Cherryville, NC
Diplomate, American Board of Clinical Lipidology
Cardiologist
Stern Cardiovascular Foundation
Memphis, TN
Diplomate, American Board of Clinical Lipidology
An accumulating body of evidence has implicated hypertriglyceridemia as a treatable risk factor for the prevention of atherosclerotic cardiovascular diseases (ASCVD).(1) Most notably, the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) provided renewed and convincing justification for triglyceride-lowering therapy in at-risk individuals with optimally controlled low-density lipoprotein (LDLC) levels.(2) The results of this landmark study have built upon
Article By:
Resident Physician
Department of Internal Medicine
Mayo Clinic
Phoenix, AZ
Associate Professor of Cardiology
System Director, Cardiovascular Prevention
Northwell Health
Director, Women’s Heart Health
Lenox Hill Hospital, New York
Certified Lipidologist
New York, NY
Diplomate, American Board of Clinical Lipidology
Familial hypercholesterolemia (FH) is an autosomal codominant genetic disorder of lipoprotein metabolism associated with disproportionately high levels of lowdensity lipoprotein cholesterol (LDL-C) and an increased risk of developing premature atherosclerotic cardiovascular disease (ASCVD) and valvular aortic stenosis.(1,2) Heterozygous FH (HeFH) affects all races and ethnicities and is prevalent in approximately 1 in 220 individuals, though an estimated 90% of those affected are presently un
Article By:
Department of Chronic Disease Epidemiology
Yale School of Public Health
New Haven, CT
Department of Medicine
Division of Cardiovascular Medicine
University of Pennsylvania
Philadelphia, PA
Department of Medicine
Division of Cardiovascular Medicine
University of Pennsylvania
Philadelphia, PA
Department of Obstetrics and Gynecology
University of Pennsylvania
Philadelphia, PA
Editor, LipidSpin
Department of Medicine
Division of Transitional Medicine and Human Genetics
Internal Medicine
University of Pennsylvania
Philadelphia, PA
Diplomate, American Board of Clinical Lipidology
Cardiovascular disease (CVD) is the leading cause of death worldwide, accounting for nearly 18 million deaths in 2017 with 859,125 of those occurring in the United States – a number higher than death from all forms of cancer combined.(1) Unfortunately, this global number is anticipated to rise to over 22 million by 2030.
About one third of American adults have some form of CVD, with costs of the management of these conditions surpassing $351 billion between 2014 and 2015.(1)
Article By:
Preventative Cardiology Fellow
Lenox Hill Hospital
New York, NY
Director, Cardiovascular Health and Lipidology
Associate Professor of Medicine
Zucker School of Medicine
Sandra Atlas Bass Heart Hospital
North Shore University Hospital
Manhasset, NY
Diplomate, American Board of Clinical Lipidology
“In the long history of humankind (and of animal kind too) those who learned to collaborate and improvise most effectively have prevailed” ~ Charles R. Darwin
Article By:
Editor, LipidSpin
Medical Director, Lipid Clinic and Physician Advisor
Ascension Wisconsin All Saints
Racine, WI
Diplomate, American Board of Clinical Lipidology
As I write this, it is nearly impossible to address anything related to health care and medicine without mentioning COVID19. Indeed, this pandemic has effected changes most of us never imagined. Lives have been lost. Families have suffered. Unemployment is rampant. The tension between restoring the economy and respecting the virus is palpable. There remains much uncertainty.
Article By:
Past President, Southeast Lipid Association
Medical Director, Hometown Direct Care
Hometown Direct Consulting
Cherryville, NC
Diplomate, American Board of Clinical Lipidology